A citation-based method for searching scientific literature

Guojuan Jiang, Wanglong Deng, Yang Liu, Chengde Wang. Mol Med Rep 2020
Times Cited: 12

List of co-cited articles
53 articles co-cited >1

Times Cited
  Times     Co-cited

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018

Clinical trials for BET inhibitors run ahead of the science.
Guillaume Andrieu, Anna C Belkina, Gerald V Denis. Drug Discov Today Technol 2016

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.
Azadeh Hajmirza, Anouk Emadali, Arnaud Gauthier, Olivier Casasnovas, Rémy Gressin, Mary B Callanan. Biomedicines 2018

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai,[...]. Lancet Haematol 2016

BET inhibitors: a novel epigenetic approach.
D B Doroshow, J P Eder, P M LoRusso. Ann Oncol 2017

BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Mingchen Ba, Hui Long, Zhaofei Yan, Shuai Wang, Yinbing Wu, Yinuo Tu, Yuanfeng Gong, Shuzhong Cui. J Cell Biochem 2018

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, Jean-Marie Michot, Carlo Lucchesi, Andrea Varga, Jean-Michel Coindre, Stephen J Blakemore, Alicia Clawson, Benjamin Suttle,[...]. Lancet Oncol 2018

Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo.
Valentina Maggisano, Marilena Celano, Rocco Malivindi, Ines Barone, Donato Cosco, Catia Mio, Chiara Mignogna, Salvatore Panza, Giuseppe Damante, Massimo Fresta,[...]. Cancers (Basel) 2019

BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin.
Ballachanda N Devaiah, Chanelle Case-Borden, Anne Gegonne, Chih Hao Hsu, Qingrong Chen, Daoud Meerzaman, Anup Dey, Keiko Ozato, Dinah S Singer. Nat Struct Mol Biol 2016

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011

Latent enhancers activated by stimulation in differentiated cells.
Renato Ostuni, Viviana Piccolo, Iros Barozzi, Sara Polletti, Alberto Termanini, Silvia Bonifacio, Alessia Curina, Elena Prosperini, Serena Ghisletti, Gioacchino Natoli. Cell 2013

Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Felice Ho-Ching Tsang, Cheuk-Ting Law, Tsz-Ching Chloe Tang, Carol Lai-Hung Cheng, Don Wai-Ching Chin, Wing-Sum Vincy Tam, Lai Wei, Carmen Chak-Lui Wong, Irene Oi-Lin Ng, Chun-Ming Wong. Hepatology 2019

BET bromodomains mediate transcriptional pause release in heart failure.
Priti Anand, Jonathan D Brown, Charles Y Lin, Jun Qi, Rongli Zhang, Pedro Calderon Artero, M Amer Alaiti, Jace Bullard, Kareem Alazem, Kenneth B Margulies,[...]. Cell 2013

RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Kevin G McLure, Emily M Gesner, Laura Tsujikawa, Olesya A Kharenko, Sarah Attwell, Eric Campeau, Sylwia Wasiak, Adam Stein, Andre White, Eric Fontano,[...]. PLoS One 2013

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Sarah Picaud, Christopher Wells, Ildiko Felletar, Deborah Brotherton, Sarah Martin, Pavel Savitsky, Beatriz Diez-Dacal, Martin Philpott, Chas Bountra, Hannah Lingard,[...]. Proc Natl Acad Sci U S A 2013

Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis.
Ji-Eun Lee, Young-Kwon Park, Sarah Park, Younghoon Jang, Nicholas Waring, Anup Dey, Keiko Ozato, Binbin Lai, Weiqun Peng, Kai Ge. Nat Commun 2017

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones.
Tomohiko Kanno, Yuka Kanno, Gary LeRoy, Eric Campos, Hong-Wei Sun, Stephen R Brooks, Golnaz Vahedi, Tom D Heightman, Benjamin A Garcia, Danny Reinberg,[...]. Nat Struct Mol Biol 2014

BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.
Anand S Bhagwat, Jae-Seok Roe, Beverly Y L Mok, Anja F Hohmann, Junwei Shi, Christopher R Vakoc. Cell Rep 2016

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011

Coactivator condensation at super-enhancers links phase separation and gene control.
Benjamin R Sabari, Alessandra Dall'Agnese, Ann Boija, Isaac A Klein, Eliot L Coffey, Krishna Shrinivas, Brian J Abraham, Nancy M Hannett, Alicia V Zamudio, John C Manteiga,[...]. Science 2018

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011

BET bromodomain inhibition of MYC-amplified medulloblastoma.
Pratiti Bandopadhayay, Guillaume Bergthold, Brian Nguyen, Simone Schubert, Sharareh Gholamin, Yujie Tang, Sara Bolin, Steven E Schumacher, Rhamy Zeid, Sabran Masoud,[...]. Clin Cancer Res 2014

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019

Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Ana S Leal, Charlotte R Williams, Darlene B Royce, Patricia A Pioli, Michael B Sporn, Karen T Liby. Cancer Lett 2017

Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Kausik K Ray, Stephen J Nicholls, Henry D Ginsberg, Jan O Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P Toth, Norman Wong, Jeffrey L Cummings, Michael Sweeney,[...]. Am Heart J 2019

Two faces of brd4: mitotic bookmark and transcriptional lynchpin.
Ballachanda N Devaiah, Dinah S Singer. Transcription 2013

Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants.
Stephen C J Parker, Michael L Stitzel, D Leland Taylor, Jose Miguel Orozco, Michael R Erdos, Jennifer A Akiyama, Kelly Lammerts van Bueren, Peter S Chines, Narisu Narisu, Brian L Black,[...]. Proc Natl Acad Sci U S A 2013

Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Stephen J Nicholls, Allan Gordon, Jan Johansson, Kathy Wolski, Christie M Ballantyne, John J P Kastelein, Allen Taylor, Marilyn Borgman, Steven E Nissen. J Am Coll Cardiol 2011

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
Kausik K Ray, Stephen J Nicholls, Kevin A Buhr, Henry N Ginsberg, Jan O Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P Toth, Norman Wong, Michael Sweeney,[...]. JAMA 2020

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005

Hepatocellular carcinoma: a review.
Julius Balogh, David Victor, Emad H Asham, Sherilyn Gordon Burroughs, Maha Boktour, Ashish Saharia, Xian Li, R Mark Ghobrial, Howard P Monsour. J Hepatocell Carcinoma 2016

Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1.
Sheng-xian Yuan, Jie Wang, Fu Yang, Qi-fei Tao, Jin Zhang, Li-li Wang, Yuan Yang, Hui Liu, Zhen-guang Wang, Qing-guo Xu,[...]. Hepatology 2016

Modification of enhancer chromatin: what, how, and why?
Eliezer Calo, Joanna Wysocka. Mol Cell 2013

A unique chromatin signature uncovers early developmental enhancers in humans.
Alvaro Rada-Iglesias, Ruchi Bajpai, Tomek Swigut, Samantha A Brugmann, Ryan A Flynn, Joanna Wysocka. Nature 2011

Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome.
Nathaniel D Heintzman, Rhona K Stuart, Gary Hon, Yutao Fu, Christina W Ching, R David Hawkins, Leah O Barrera, Sara Van Calcar, Chunxu Qu, Keith A Ching,[...]. Nat Genet 2007

Therapeutic targeting of transcriptional cyclin-dependent kinases.
Matthew D Galbraith, Heather Bender, Joaquín M Espinosa. Transcription 2019

Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Henry E Pelish, Brian B Liau, Ioana I Nitulescu, Anupong Tangpeerachaikul, Zachary C Poss, Diogo H Da Silva, Brittany T Caruso, Alexander Arefolov, Olugbeminiyi Fadeyi, Amanda L Christie,[...]. Nature 2015

Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Stephen Philip, Malika Kumarasiri, Theodosia Teo, Mingfeng Yu, Shudong Wang. J Med Chem 2018

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.